Lakefront Biotherapeutics | GLPG - Assets


Lakefront Biotherapeutics reported EUR3.35B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
argenx SE USD 10.03B 1.35B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Genmab DKK 12.52B 139M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
GRIFOLS EUR 20.09B 12M Jun/2026
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
Incyte USD 7.87B 533.53M Jun/2026
Merck EUR 52.69B 383M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
UCB EUR 18.16B 971M Dec/2025
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026